DTRT Health Acquisition Corp. - Quarter Report: 2022 September (Form 10-Q)
Table of Contents
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Delaware |
001-40774 |
86-3336784 | ||
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) | ||
1415 West 22nd Street, Tower Floor Oak Brook, |
60523 | |||
(Address of principal executive offices) |
(Zip Code) |
Title of Each Class: |
Trading Symbol: |
Name of Each Exchange on Which Registered: | ||
Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant |
DTRTU |
The Nasdaq Stock Market LLC | ||
Class A Common Stock, par value $0.0001 per share |
DTRT |
The Nasdaq Stock Market LLC | ||
Redeemable warrants, each warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share |
DTRTW |
The Nasdaq Stock Market LLC |
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
Table of Contents
DTRT HEALTH ACQUISITION CORP.
Form 10-Q
Table of Contents
Page | ||||||
Item 1. |
1 | |||||
Condensed Balance Sheets as of September 30, 2022 (unaudited) and December 31, 2021 |
1 | |||||
2 | ||||||
3 | ||||||
4 | ||||||
5 | ||||||
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
21 | ||||
Item 3. |
25 | |||||
Item 4. |
25 | |||||
Item 1. |
26 | |||||
Item 1A. |
26 | |||||
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities |
26 | ||||
Item 3. |
27 | |||||
Item 4. |
27 | |||||
Item 5. |
27 | |||||
Item 6. |
27 | |||||
Table of Contents
Item 1. |
Condensed Financial Statements |
September 30, 2022 |
December 31, 2021 |
|||||||
(unaudited) |
||||||||
Assets: |
||||||||
Current assets: |
||||||||
Cash |
$ | 69,771 | $ | 342,152 | ||||
Prepaid expenses |
489,460 | 861,218 | ||||||
|
|
|
|
|||||
Total current assets |
559,231 | 1,203,370 | ||||||
Investments held in Trust Account |
235,611,624 | 234,616,804 | ||||||
|
|
|
|
|||||
Total Assets |
$ |
236,170,855 |
$ |
235,820,174 |
||||
|
|
|
|
|||||
Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders’ Deficit: |
||||||||
Current liabilities: |
||||||||
Due to related parties |
$ | 21,671 | $ | 6,668 | ||||
Accounts payable |
39,750 | — | ||||||
Accrued expenses |
143,100 | 164,900 | ||||||
Franchise tax payable |
61,195 | 138,680 | ||||||
Income tax payable |
256,369 | — | ||||||
|
|
|
|
|||||
Total current liabilities |
522,085 | 310,248 | ||||||
Deferred underwriting commissions in connection with the Initial Public Offering |
8,050,000 | 8,050,000 | ||||||
Derivative warrant liabilities |
3,472,000 | 5,824,000 | ||||||
|
|
|
|
|||||
Total Liabilities |
12,044,085 | 14,184,248 | ||||||
Commitments and Contingencies |
||||||||
Class A common stock, $0.0001 par value; 23,000,000 shares subject to possible redemption at $10.23 and $10.20 per share at September 30, 2022 and December 31, 2021, respectively |
235,194,060 | 234,600,000 | ||||||
Stockholders’ Deficit: |
||||||||
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding |
— | — | ||||||
Class A common stock, $0.0001 par value; 380,000,000 shares authorized at September 30, 2022 and December 31, 2021 |
— | — | ||||||
Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 5,750,000 shares issued and outstanding at September 30, 2022 and December 31, 2021 |
575 | 575 | ||||||
Additional paid-in capital |
— | — | ||||||
Accumulated deficit |
(11,067,865 | ) | (12,964,649 | ) | ||||
|
|
|
|
|||||
Total Stockholders’ Deficit |
(11,067,290 | ) | (12,964,074 | ) | ||||
|
|
|
|
|||||
Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders’ Deficit |
$ |
236,170,855 |
$ |
235,820,174 |
||||
|
|
|
|
For the Three Months Ended September 30, |
For the Nine Months Ended September 30, |
For the Period from April 19, 2021 (inception) through |
||||||||||||||
2022 |
2021 |
2022 |
September 30, 2021 |
|||||||||||||
General and administrative expenses |
$ | 209,792 | $ | 34,426 | $ | 662,643 | $ | 37,962 | ||||||||
General and administrative expenses - Related Party |
5,001 | — | 15,003 | — | ||||||||||||
Franchise tax expenses |
49,863 | 49,315 | 147,945 | 88,817 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Loss from operations |
(264,656 | ) | (83,741 | ) | (825,591 | ) | (126,779 | ) | ||||||||
Other income (expenses) |
||||||||||||||||
Change in Fair Value of Derivative Warrant Liabilities |
(2,688,000 | ) | (336,000 | ) | 2,352,000 | (336,000 | ) | |||||||||
Interest Earned - trust |
1,047,583 | 4,576 | 1,220,785 | 4,576 | ||||||||||||
Interest Income - checking |
8 | 23 | 19 | 23 | ||||||||||||
Loss upon issuance of private placement warrants |
— | (4,256,000 | ) | — | (4,256,000 | ) | ||||||||||
Offering costs associated with derivative warrant liabilities |
— | (40,524 | ) | — | (40,524 | ) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Income (loss) before income taxes |
(1,905,065 | ) | (4,711,666 | ) | 2,747,213 | (4,754,704 | ) | |||||||||
Income tax expense |
(256,369 | ) | — | (256,369 | ) | — | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net income (loss) |
$ |
(2,161,434 |
) |
$ |
(4,711,666 |
) |
$ |
2,490,844 |
$ |
(4,754,704 |
) | |||||
|
|
|
|
|
|
|
|
|||||||||
Weighted average shares outstanding of Class A common stock, basic and diluted |
23,000,000 |
6,000,000 |
23,000,000 |
3,887,324 |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Basic and diluted net income (loss) per share, Class A common stock |
$ |
(0.08 |
) |
$ |
(0.42 |
) |
$ |
0.09 |
$ |
(0.53 |
) | |||||
|
|
|
|
|
|
|
|
|||||||||
Weighted average shares outstanding of Class B common stock, basic and diluted |
5,750,000 |
5,195,652 |
5,750,000 |
5,126,761 |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Basic and diluted net income share,stock |
$ |
(0.08 |
) |
$ |
(0.42 |
) |
$ |
0.09 |
$ |
(0.53 |
) | |||||
|
|
|
|
|
|
|
|
Common Stock |
Total |
|||||||||||||||||||||||||||
Class A |
Class B |
Additional Paid-In |
Accumulated |
Stockholders’ |
||||||||||||||||||||||||
Stock |
Amount |
Stock |
Amount |
Capital |
Deficit |
Deficit |
||||||||||||||||||||||
Balance - December 31, 2021 |
— |
— |
5,750,000 |
$ |
575 |
— |
$ |
(12,964,649 |
) |
$ |
(12,964,074 |
) | ||||||||||||||||
Net income |
— | — | — | — | — | 2,755,535 | 2,755,535 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance - March 31, 2022 (unaudited) |
— |
— |
5,750,000 |
575 |
— |
(10,209,114 |
) |
(10,208,539 |
) | |||||||||||||||||||
Net income |
— | — | — | — | — | 1,896,743 | 1,896,743 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance - June 30, 2022 (unaudited) |
— |
— |
5,750,000 |
$ |
575 |
— |
$ |
(8,312,371 |
) |
$ |
(8,311,796 |
) | ||||||||||||||||
Increase in redemption value of Class A common stock subject to possible redemption |
— | — | — | — | — | (594,060 | ) | (594,060 | ) | |||||||||||||||||||
Net l oss |
— | — | — | — | — | (2,161,434 | ) | (2,161,434 | ) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance - September 30, 2022 (unaudited) |
— |
$ |
— |
5,750,000 |
$ |
575 |
$ |
— |
$ |
(11,067,865 |
) |
$ |
(11,067,290 |
) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock |
Total |
|||||||||||||||||||||||||||
Class A |
Class B |
Additional Paid-In |
Accumulated |
Stockholders’ |
||||||||||||||||||||||||
Stock |
Amount |
Stock |
Amount |
Capital |
Deficit |
Deficit |
||||||||||||||||||||||
Balance - April 19, 2021 (inception) |
— |
$ |
— |
— |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
||||||||||||||||
Issuance of Class B common stock to Sponsor |
— | — | 5,750,000 | 575 | 24,425 | — | 25,000 | |||||||||||||||||||||
Net loss |
— | — | — | — | — | (43,038 | ) | (43,038 | ) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance - June 30, 2021 (unaudited) |
— |
— |
5,750,000 |
575 |
24,425 |
(43,038 |
) |
(18,038 |
) | |||||||||||||||||||
Accretion of Class A common stock redemption amount |
— | — |
— | — |
(24,425 | ) | (17,828,287 | ) | (17,852,712 | ) | ||||||||||||||||||
Net loss |
— | — | — | — | — | (4,711,666 | ) | (4,711,666 | ) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance - September 30, 2021 (unaudited) |
— |
$ |
— |
5,750,000 |
$ |
575 |
$ |
— |
$ |
(22,582,991 |
) |
$ |
(22,582,416 |
) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Nine |
For the Period from |
|||||||
Months ended |
April 19, 2021 |
|||||||
September 30, |
(inception) through |
|||||||
2022 |
September 30, 2021 |
|||||||
Cash Flows from Operating Activities: |
||||||||
Net income (loss) |
$ | 2,490,844 | $ | (4,754,704 | ) | |||
Adjustments to reconcile net income (loss) to net cash used in operating activities: |
||||||||
Interest income earned on Trust Account |
(1,220,785 | ) | (4,574 | ) | ||||
Loss upon issuance of Private Placement Warrants |
— | 4,256,000 | ||||||
Offering costs associated with derivative warrant liabilities |
— | 40,524 | ||||||
Change in fair value of derivative warrant liabilities |
(2,352,000 | ) | 336,000 | |||||
Changes in operating assets and liabilities: |
||||||||
Prepaid expenses |
371,758 | (1,039,267 | ) | |||||
Franchise tax payable |
(77,485 | ) | 88,817 | |||||
Accounts payable |
39,750 | 1,014,750 | ||||||
Income tax payable |
256,369 | — | ||||||
Due to related part ies |
15,003 | — | ||||||
Accrued expenses |
(21,800 | ) | (6,181 | ) | ||||
|
|
|
|
|||||
Net cash used in operating activities |
(498,346 | ) | (68,635 | ) | ||||
|
|
|
|
|||||
Cash Flows from Investing Activities |
||||||||
Withdraw from trust for payment of franchise tax |
225,965 | — | ||||||
Principal deposited in Trust Account |
— | (234,600,000 | ) | |||||
|
|
|
|
|||||
Net cash provided by (used in) investing activities |
225,965 | (234,600,000 | ) | |||||
|
|
|
|
|||||
Cash Flows from Financing Activities: |
||||||||
Proceeds from issuance of Class B common stock to Sponsor |
— | 25,000 | ||||||
Proceeds from note payable to related party |
— | 300,000 | ||||||
Repayment of note payable to related party |
— | (300,000 | ) | |||||
Proceeds received from Initial Public Offering, gross |
— | 230,000,000 | ||||||
Proceeds received from Private Placement |
— | 11,200,000 | ||||||
Offering costs paid |
— | (5,095,674 | ) | |||||
|
|
|
|
|||||
Net cash provided by financing activities |
— | 236,129,326 | ||||||
|
|
|
|
|||||
Net change in cash |
(272,381 | ) | 1,460,691 | |||||
Cash - beginning of the period |
342,152 | — | ||||||
|
|
|
|
|||||
Cash - end of the period |
$ |
69,771 |
$ |
1,460,691 |
||||
|
|
|
|
|||||
Supplemental disclosure of noncash activities: |
||||||||
Offering costs included in accounts payable |
$ | — | $ | 15,000 | ||||
Offering costs included in accrued expenses |
$ | — | $ | 132,563 | ||||
Deferred underwriting commissions in connection with the Initial Public Offering |
$ | — | $ | 8,050,000 |
• | Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; |
• | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
• | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
For the Three Months Ended September 30, 2022 |
For the Three Months Ended September 30, 2021 |
For the Nine Months Ended September 30, 2022 |
For the Period from April 19, 2021 (inception) through September 30, 2021 |
|||||||||||||||||||||||||||||
Class A |
Class B |
Class A |
Class B |
Class A |
Class B |
Class A |
Class B |
|||||||||||||||||||||||||
Basic and diluted net income (loss) per common stock: |
||||||||||||||||||||||||||||||||
Numerator: |
||||||||||||||||||||||||||||||||
Allocation of net income ( loss ) - basic and diluted |
$ | (1,729,147 | ) | $ | (432,287 | ) | $ | (2,525,087 | ) | $ | (2,186,579 | ) | $ |
1,992,675 |
$ |
498,169 |
$ |
(2,050,466 |
) |
$ |
(2,704,238 |
) | ||||||||||
Denominator: |
||||||||||||||||||||||||||||||||
Basic and diluted weighted average common stocks outstanding |
23,000,000 | 5,750,000 | 6,000,000 | 5,195,652 | 23,000,000 |
5,750,000 |
3,887,324 |
5,126,761 |
||||||||||||||||||||||||
Basic and diluted net income ( loss ) per common stock |
$ | (0.08 | ) | $ | (0.08 | ) | $ | (0.42 | ) | $ | (0.42 | ) | $ |
0.09 |
$ |
0.09 |
$ |
(0.53 |
) |
$ |
(0.53 |
) | ||||||||||
Gross Proceeds |
$ | 230,000,000 | ||
Less: |
||||
Class A common stock issuance costs |
(13,245,900 | ) | ||
Plus: |
||||
Accretion of carrying value to redemption value |
17,845,900 | |||
Class A common stock subject to possible redemption at December 31, 2021 |
234,600,000 |
|||
Increase in redemption value of Class A common stock subject to possible redemption |
594,060 |
|||
Class A common stock subject to possible redemption at September 30, 2022 |
$ | 235,194,060 | ||
• | in whole and not in part; |
• | at a price of $0.01 per warrant; |
• | upon a minimum of 30 days’ prior written notice of redemption; and |
• | if, and only if, the last reported sale price (the “closing price”) of Class A common stock equals or exceeds $18.00 per share (as adjusted) for any 20-trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. |
Description |
Quoted Prices in Active Markets (Level 1) |
Significant Other Observable Inputs (Level 2) |
Significant Other Unobservable Inputs (Level 3) |
|||||||||
Assets: |
||||||||||||
Investments held in Trust Account - U.S. Treasury Securities |
$ | 235,611,624 | $ | — | $ | — | ||||||
Liabilities: |
||||||||||||
Private Placement Warrants |
$ | — | $ | — | $ | 3,472,000 |
Description |
Quoted Prices in Active Markets (Level 1) |
Significant Other Observable Inputs (Level 2) |
Significant Other Unobservable Inputs (Level 3) |
|||||||||
Assets: |
||||||||||||
Investments held in Trust Account - U.S. Treasury Securities |
$ | 234,616,804 | $ | — | $ | — | ||||||
Liabilities: |
||||||||||||
Private Placement Warrants |
$ | — | $ | — | $ | 5,824,000 |
As of September 30, 2022 |
As of December 31, 2021 |
|||||||
Exercise price |
$ | 11.50 | $ | 11.50 | ||||
Stock price |
$ | 10.16 | $ | 9.98 | ||||
Volatility |
7.5 | % | 10.0 | % | ||||
Term (years) |
5.50 | 5.50 | ||||||
Risk-free rate |
4.00 | % | 1.30 | % | ||||
Dividend yield |
0.0 | % | 0.0 | % |
Derivative warrant liabilities at December 31, 2021 |
$ | 5,824,000 | ||
Change in fair value of derivative warrant liabilities-private |
(3,024,000 | ) | ||
|
|
|||
Derivative warrant liabilities at March 31, 2022 |
$ | 2,800,000 | ||
Change in fair value of derivative warrant liabilities-private |
(2,016,000 | ) | ||
|
|
|||
Derivative warrant liabilities at June 30, 2022 |
$ | 784,000 | ||
Change in fair value of derivative warrant liabilities-private |
2,688,000 | |||
|
|
|||
Derivative warrant liabilities at September 30, 2022 |
$ | 3,472,000 | ||
|
|
Derivative warrant liabilities at April 19, 2021 (inception) |
$ | — | ||
Issuance of Private Placement Warrants |
15,456,000 | |||
Change in fair value of derivative warrant liabilities-private |
336,000 | |||
|
|
|||
Derivative warrant liabilities at September 30, 2021 |
$ | 15,792,000 | ||
|
|
Table of Contents
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations. |
References to the “Company,” “DTRT Health Acquisition Corp.,” “our,” “us” or “we” refer to DTRT Health Acquisition Corp. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited interim condensed financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 1, 2022, as supplemented by the Company’s Quarterly Reports on Form 10-Q for the period ended March 30, 2022 and June 30, 2022, filed with the SEC on May 13, 2022 and August 12, 2022, respectively. The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Overview
We are a blank check company incorporated in Delaware on April 19, 2021. We were formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). We are an emerging growth company and, as such, we are subject to all of the risks associated with emerging growth companies.
Our sponsor is DTRT Health Sponsor LLC, a Delaware limited liability company (the “Sponsor”). The registration statement for our initial public offering (the “Initial Public Offering”) was declared effective on September 1, 2021. On September 7, 2021, we consummated the Initial Public Offering of 23,000,000 units (the “Units” and, with respect to the Class A common stock included in the Units being offered, the “Public Shares”), which includes the exercise in full of the underwriters’ option to purchase 3,000,000 Units, at $10.00 per Unit, generating gross proceeds of $230,000,000, and incurring offering costs of approximately $13,300,000, of which approximately $8,100,000 was for deferred underwriting commissions and approximately $71,000 was for offering costs allocated to derivative warrant liabilities.
Simultaneously with the closing of the Initial Public Offering, we consummated the private placement (“Private Placement”) of 11,200,000 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of $11,200,000.
Upon the closing of the Initial Public Offering and the Private Placement, $234,600,000 ($10.20 per Unit) of the net proceeds of the sale of the Units in the Initial Public Offering and of the Private Placement Warrants were placed in a trust account (the “Trust Account”) and invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 under the Investment Company Act, as determined by us, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below.
21
Table of Contents
Proposed Business Combination
On September 28, 2022, we entered into an agreement and plan of merger by and among the Company, Grizzly New Pubco, Inc. (“New Pubco”), a wholly owned subsidiary of the Company, Grizzly Merger Sub, Inc., a wholly owned subsidiary of New Pubco (“Grizzly Merger Sub”), Consumer Direct Holdings, Inc., a Montana corporation (“CDH”) and the Pre-Closing Holder Representative (as defined therein) (as it may be amended and/or restated from time to time, the “Merger Agreement”). The Merger Agreement has been unanimously approved by the Company’s and CDH’s board of directors and adopted by CDH’s shareholders. If the Merger Agreement is approved by the Company’s stockholders and the transactions contemplated by the Merger Agreement are consummated, the CDH shareholders will form a Delaware corporation (“Newco”) and contribute all of the issued and outstanding shares of CDH common stock to Newco in exchange for shares of Newco common stock. Grizzly Merger Sub will merge with and into the Company, the Company’s stockholders will receive shares of New Pubco common stock in exchange for their shares of the Company’s common stock and New Pubco private placement warrants in exchange for their Private Placement Warrants, and the Company will be the surviving entity in the merger as a wholly owned subsidiary of New Pubco (the “First Merger”), and immediately following the First Merger, the Company will convert into an limited liability company (the “Conversion”). Following the First Merger and the Conversion, Newco will merge with and into New Pubco, with New Pubco surviving the merger (the “Second Merger” and together with the First Merger and all other transactions contemplated by the Merger Agreement, the “Proposed Business Combination”). In connection with the consummation of the Proposed Business Combination, New Pubco will be renamed “Consumer Direct Care Network, Inc.” (“CDCN”). The board of directors of the post-closing public entity, CDCN, will be comprised of a total of seven (7) directors, five (5) of whom will be nominated by the pre-closing shareholders of CDH and two (2) of whom will be nominated by the Sponsor.
In connection with the First Merger and without any further action on the part of any party, each share of Class A common stock and Class B common stock of the Company will be converted into one share of common stock of New Pubco, and each private placement warrant and public warrant will be converted into one private placement warrant of New Pubco and one public warrant of New Pubco, respectively, each exercisable for one share of New Pubco common stock.
Under the Merger Agreement, in connection with the Second Merger, the Company has agreed to indirectly acquire all of the outstanding equity interests of CDH for approximately $527 million in aggregate consideration, subject to specified adjustments, which will be paid at the effective time of the Proposed Business Combination. Such consideration will be paid in cash and shares of common stock of New Pubco, calculated based on the per share merger consideration value formula as set forth in the Merger Agreement and, in the case of the shares of common stock of New Pubco, calculated based on a price of $10.20 per share (the “Closing Price”). The cash consideration is expected to be $118.35 million, less certain advisor expenses, and the remainder of the aggregate consideration will be paid in shares of common stock of New Pubco. The stock consideration is subject to the following adjustments: (i) an increase for CDH’s cash on hand as of closing; (ii) a decrease for CDH’s indebtedness as of Closing; (iii) a decrease for certain advisor expenses; (iv) an increase or decrease for CDH’s working capital as compared to a working capital target; (v) an increase or decrease for the amount by which CDH’s transaction expenses are less than (or greater than) $7 million; and (vi) an increase for credited expenses paid by CDH.
The parties to the Merger Agreement have made customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants with respect to the conduct of CDH, the Company, Grizzly Merger Sub and New Pubco prior to the closing of the Proposed Business Combination.
The closing of the Proposed Business Combination is subject to certain customary conditions, including, among other things: (i) approval by the Company’s stockholders of the proposals being presented at the special meeting, (ii) the expiration or termination of the waiting period (or any extension thereof) applicable under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, (iii) the absence of a material adverse regulatory event by a governmental entity that enjoins, prohibits or makes illegal the consummation of the Proposed Business Combination, (iv) the Company obtaining financing satisfactory to CDH, (v) certain contracts of CDH and its subsidiaries that have been agreed to between the parties being in full force and effect and (vi) the approval of listing of the shares of New Pubco common stock on one of the Nasdaq market tiers.
The Merger Agreement may be terminated by the Company or CDH under certain circumstances.
22
Table of Contents
Registration Rights Agreement
At the closing of the Proposed Business Combination, New Pubco, the Company, the Sponsor, certain members of the Sponsor (the “Sponsor Members”) and the holders of CDH capital stock (the “CDH shareholders” and together with the Sponsor and the Sponsor Members, the “Holders”) will enter into a registration rights agreement (the “Registration Rights Agreement”). Pursuant to the terms of the Registration Rights Agreement, New Pubco will be obligated to file a registration statement to register the resale of certain securities of the New Pubco held by such Holders. In addition, such Holders may make a written demand to New Pubco for an underwritten offering at any time after the three hundred seventy-fifth (375th) day following the consummation of the Proposed Business Combination (or such earlier time in the event that the demand is with respect to greater than 65% of the registrable securities and New Pubco has obtained the prior written consent of the Sponsor). The Registration Rights Agreement will also provide such Holders with “piggy-back” registration rights, subject to certain requirements and customary conditions.
Liquidity and Going Concern
As of September 30, 2022, we had approximately $70,000 in our operating bank account and a working capital of approximately $37,000.
Our liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $25,000 from our Sponsor to purchase Class B common stock, par value $0.0001 per share (the “Founder Shares”) and a loan from our Sponsor of $300,000 under a promissory note (the “Note”) dated May 11, 2021. We borrowed $300,000 under the Note since its execution on May 11, 2021, and fully repaid this amount on September 7, 2021. Subsequent to the consummation of the Initial Public Offering, our liquidity will be satisfied through the net proceeds from the consummation of the Initial Public Offering and Private Placement held outside of the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, our Sponsor or an affiliate of the Sponsor, or certain of our officers and directors may, but are not obligated to, loan us funds as may be required (the “Working Capital Loans”). As of September 30, 2022, there were no amounts outstanding under any Working Capital Loans.
In connection with our assessment of going concern considerations in accordance with FASB ASC Topic 205-40, “Presentation of Financial Statements-Going Concern,” we have determined that the mandatory liquidation date and subsequent dissolution raise substantial doubt about our ability to continue as a going concern. If we are unable to complete a Business Combination by December 7, 2022 (unless such period is extended as described herein), then we will cease all operations except for the purpose of liquidating. Over this time period, we have used, and will be using, these funds for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination. The unaudited condensed financial statements do not include any adjustment that might be necessary if we are unable to continue as a going concern.
Results of Operations
Our entire activity since inception up to September 30, 2022, was in preparation for our Initial Public Offering, and since our Initial Public Offering, our search for a prospective target Business Combination. We will not generate any operating revenues until the closing and completion of our initial Business Combination, at the earliest.
For the three months ended September 30, 2022, we had a net loss of approximately $2.2 million, which consisted approximately $2.7 million change in fair value of derivative warrant liabilities, approximately $210,000 of general and administrative expenses, $5,000 related party general and administrative expense, approximately $256,000 of income tax expense, and approximately $50,000 of franchise tax expense, partially offset by approximately $1 million of interest income from investments held in the Trust Account.
For the three months ended September 30, 2021, we had a net loss of approximately $4.7 million which consisted of approximately $4.3 million loss upon issuance of Private Placement Warrants, approximately $336,000 change in fair value of derivative warrant liabilities, approximately $41,000 offering costs associated with derivative warrant liabilities, approximately $34,000 of general and administrative expenses and approximately $49,000 of franchise tax expense, offset by approximately $5,000 of interest income from investments held in the Trust Account and checking account.
23
Table of Contents
For the nine months ended September 30, 2022, we had a net income of approximately $2.5 million, which consisted of approximately $2.3 million change in fair value of derivative warrant liabilities and $1.2 million of interest income from investments held in the Trust Account, partially offset by approximately $663,000 of general and administrative expenses, $15,000 related party general and administrative expenses, approximately $256,000 of income tax expense, and approximately $148,000 of franchise tax expense.
For the period from April 19, 2021 (inception) through September 30, 2021, we had a net loss of approximately $4.75 million, which consisted of approximately $4.3 million loss upon issuance of Private Placement warrants, approximately $336,000 change in fair value of derivative warrant liabilities, approximately $41,000 offering costs associated with derivative warrant liabilities, approximately $38,000 of general and administrative expenses and approximately $89,000 of franchise tax expense, offset by approximately $5,000 of interest income from investments held in the Trust Account and the checking account.
Contractual Obligations
Registration Rights
The holders of Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans, if any, (and any shares of Class A common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) were entitled to registration rights pursuant to a registration rights agreement signed upon the consummation of the Initial Public Offering. The holders of these securities were entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. We will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriting Agreement
We granted the underwriters a 45-day option from the date of the final prospectus relating to the Initial Public Offering to purchase up to 3,000,000 additional Units to cover over-allotments, if any, at the Initial Public Offering price, less underwriting discounts and commissions. The underwriters fully exercised the over-allotment on September 7, 2021.
The underwriters were entitled to an underwriting discount of $0.20 per Unit, or $4,600,000 in the aggregate, paid upon the closing of the Initial Public Offering. In addition, the underwriters were entitled to a deferred fee of $0.35 per Unit, or approximately $8,100,000 in the aggregate. The deferred fees will become payable to the underwriters from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms of the underwriting agreement.
Critical Accounting Policies
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. A summary of our significant accounting policies is included in Note 2 to our unaudited condensed financial statements in Part I, Item 1 of this Quarterly Report. Certain of our accounting policies are considered critical, as these policies are the most important to the depiction of our financial statements and require significant, difficult or complex judgments, often employing the use of estimates about the effects of matters that are inherently uncertain. Such policies are summarized in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section in our 2021 Annual Report on Form 10-K filed with the SEC on April 1, 2022. There have been no significant changes in the application of our critical accounting policies during the three and nine months ended September 30, 2022.
Recent Accounting Pronouncements
See Note 2 to the unaudited condensed financial statements included in Part I, Item 1 of this Quarterly Report for a discussion of recent accounting pronouncements.
24
Table of Contents
Off-Balance Sheet Arrangements
As of September 30, 2022, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.
JOBS Act
The JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify as an “emerging growth company” and under the JOBS Act are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, the unaudited condensed financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.
Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our Initial Public Offering or until we are no longer an “emerging growth company,” whichever is earlier.
Item 3. | Quantitative and Qualitative Disclosures About Market Risk |
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.
The net proceeds of the Initial Public Offering, including amounts in the Trust Account, will be invested in U.S. government securities with a maturity of 185 days or less or in money market funds that meet certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended, that invest only in direct U.S. government treasury obligations. Due to the short-term nature of these investments, we believe there will be no associated material exposure to interest rate risk.
We have not engaged in any hedging activities since our inception, and we do not expect to engage in any hedging activities with respect to the market risk to which we are exposed.
Item 4. | Controls and Procedures |
Evaluation of Disclosure Controls and Procedures
Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this Report, is recorded, processed, summarized, and reported within the time period specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our chief executive officer and chief financial officer (our “Certifying Officers”), the effectiveness of our disclosure controls and procedures as of September 30, 2022, pursuant to Rule 13a-15(b) under the Exchange Act. Based upon that evaluation, our Certifying Officers concluded that, as of September 30, 2022, our disclosure controls and procedures were effective.
25
Table of Contents
We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II-OTHER INFORMATION
Item 1. | Legal Proceedings |
None.
Item 1A. | Risk Factors |
Except as set forth below, as of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K filed with the SEC on April 1, 2022, as supplemented by our Quarterly Reports on Form 10-Q for the three months ended March 31, 2022 and June 30, 2022, filed with the SEC on May 13, 2022 and August 12, 2022, respectively. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.
Recent increases in inflation in the United States and elsewhere could make it more difficult for us to complete our initial Business Combination.
Recent increases in inflation in the United States and elsewhere may lead to increased price volatility for publicly traded securities, including ours, or other national, regional or international economic disruptions, any of which could make it more difficult for us to complete our initial Business Combination.
If we are deemed to be an investment company for purposes of the Investment Company Act, we would be required to institute burdensome compliance requirements and our activities would be severely restricted and, as a result, we may abandon our efforts to consummate an initial Business Combination and liquidate.
On March 30, 2022, the SEC issued proposed rules (the “SPAC Rule Proposals”) relating to, among other things, circumstances in which SPACs could potentially be subject to the Investment Company Act and the regulations thereunder. The SPAC Rule Proposals would provide a safe harbor for such companies from the definition of “investment company” under Section 3(a)(1)(A) of the Investment Company Act, provided that a SPAC satisfies certain criteria, including a limited time period to announce and complete a de-SPAC transaction. Specifically, to comply with the safe harbor, the SPAC Rule Proposals would require a company to file a Current Report on Form 8-K announcing that it has entered into an agreement with a target company for an initial business combination no later than 18 months after the effective date of its registration statement for its initial public offering (the “IPO Registration Statement”). The company would then be required to complete its initial business combination no later than 24 months after the effective date of the IPO Registration Statement.
Because the SPAC Rule Proposals have not yet been adopted, there is currently uncertainty concerning the applicability of the Investment Company Act to a SPAC that has not entered into a definitive agreement within 18 months after the effective date of the IPO Registration Statement or that may not complete its initial business combination within 24 months after such date. If we do not enter into a definitive initial business combination agreement within 18 months after the effective date of our IPO Registration Statement and do not complete our initial Business Combination within 24 months of such date (subject to the approval of an extension by our stockholders), it is possible that a claim could be made that we have been operating as an unregistered investment company.
If we are deemed to be an investment company under the Investment Company Act, our activities would be severely restricted. In addition, we would be subject to burdensome compliance requirements. We do not believe that our principal activities will subject us to regulation as an investment company under the Investment Company Act. However, if we are deemed to be an investment company and subject to compliance with and regulation under the Investment Company Act, we would be subject to additional regulatory burdens and expenses for which we have not allotted funds. As a result, unless we are able to modify our activities so that we would not be deemed an investment company, we would expect to abandon our efforts to complete an initial Business Combination and instead to liquidate.
To mitigate the risk that we might be deemed to be an investment company for purposes of the Investment Company Act, we may, at any time, instruct the trustee to liquidate the securities held in the Trust Account and instead to hold the funds in the Trust Account in cash until the earlier of the consummation of an initial Business Combination or our liquidation. As a result, following the liquidation of securities in the Trust Account, we would likely receive minimal interest, if any, on the funds held in the Trust Account, which would reduce the dollar amount the Public Stockholders would receive upon any redemption or liquidation of the Company.
The funds in the Trust Account have, since our Initial Public Offering, been held only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds investing solely in U.S. government treasury obligations and meeting certain conditions under Rule 2a-7 under the Investment Company Act. However, to mitigate the risk of us being deemed to be an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act) and thus subject to regulation under the Investment Company Act, we may, at any time, on or prior to the date that is 24 months after the effective date of the IPO Registration Statement (subject to the approval of an extension by our stockholders), instruct the trustee with respect to the Trust Account to liquidate the U.S. government treasury obligations or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash until the earlier of consummation of an initial Business Combination or liquidation of the Company. Following such liquidation of the securities held in the Trust Account, we would likely receive minimal interest, if any, on the funds held in the Trust Account. However, interest previously earned on the funds held in the Trust Account still may be released to us to pay our taxes, if any, and certain other expenses as permitted. As a result, any decision to liquidate the securities held in the Trust Account and thereafter to hold all funds in the Trust Account in cash would reduce the dollar amount the Public Stockholders would receive upon any redemption or liquidation of the Company.
In addition, even prior to the date that is 24 months after the effective date of the IPO Registration Statement (subject to the approval of an extension by our stockholders), we may be deemed to be an investment company. The longer that the funds in the Trust Account are held in short-term U.S. government treasury obligations or in money market funds invested exclusively in such securities, even prior to the date that is 24 months after the effective date of the IPO Registration Statement (subject to the approval of an extension by our stockholders), the greater the risk that we may be considered an unregistered investment company, in which case we may be required to liquidate the Company. Accordingly, we may determine, in our discretion, to liquidate the securities held in the Trust Account at any time, even prior to the date that is 24 months after the effective date of the IPO Registration Statement (subject to the approval of an extension by our stockholders), and instead hold all funds in the Trust Account in cash, which would further reduce the dollar amount the Public Stockholders would receive upon any redemption or liquidation of the Company.
Risks Relating to our Proposed Business Combination
There will be risks associated with the proposed Merger with Consumer Direct Holdings, Inc.
There will be risks associated with the Proposed Business Combination with Consumer Direct Holdings, Inc., which are discussed more fully in the proxy statement/prospectus on Form S-4 filed with the SEC by New Pubco on October 19, 2022, in connection with effectuating the Proposed Business Combination with Consumer Direct Holdings, Inc. Any of these risks could result in a material adverse effect on our results of operations, financial condition, business or prospects.
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities |
Unregistered Sales of Equity Securities
None.
Use of Proceeds
There has been no material change in the planned use of the proceeds from the Initial Public Offering and Private Placement as is described in the Company’s final prospectus related to the Initial Public Offering.
26
Table of Contents
Item 3. | Defaults Upon Senior Securities |
None.
Item 4. | Mine Safety Disclosures |
None.
Item 5. | Other Information |
None.
Item 6. | Exhibits |
* | These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. |
27
Table of Contents
PART III
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on this 10th day of November, 2022.
DTRT HEALTH ACQUISITION CORP. | ||
By: | /s/ Mark Heaney | |
Name: | Mark Heaney | |
Title: | Chief Executive Officer (Principal Executive Officer) |
28